Novo's Wegovy Reduced Liver Fat To Normal Levels In 88.5% Of Obese Adults With Excess Liver Fat At Week 72

By Reuters News

- Novo Nordisk A/S NOVOb.CO:

  • NOVO NORDISK: WEGOVY REDUCED LIVER FAT TO NORMAL LEVELS IN 88.5% OF OBESE ADULTS WITH EXCESS LIVER FAT AT WEEK 72

  • NOVO NORDISK: ANALYSIS SHOWED EVEN PARTICIPANTS WITH LOW BASELINE LIVER FAT SAW IMPROVEMENTS IN LIVER HEALTH WITH WEGOVY TREATMENT

  • NOVO NORDISK: ANALYSIS SHOWED THAT 23 OF 26 PARTICIPANTS WITH LIVER FAT ABOVE 5% REACHED BELOW 5% THRESHOLD BY WEEK 72

  • NOVO NORDISK: MEASURES SHOWED LIVER FAT DECLINED FROM 8.8% TO 3.1% AT WEEK 72 WITH WEGOVY IN STEP UP TRIAL

Further company coverage: [NOVOb.CO]

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk